Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
ApexOnco Front Page
Recent articles
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
The group is persevering with Granite, but funds might be hard to come by.
First-in-human trial initiations reveal four KRAS assets.
For $850m up front Roche gets to challenge Pfizer.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.